相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials
Xiuwen Guan et al.
ANTI-CANCER DRUGS (2015)
Annexin A4 and cancer
Bin Wei et al.
CLINICA CHIMICA ACTA (2015)
The ERCC1 and ERCC4 (XPF) genes and gene products
Mandira Manandhar et al.
GENE (2015)
Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling
Ronald L. Chandler et al.
NATURE COMMUNICATIONS (2015)
New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition
Lori W. E. van der Schoor et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Somatic Copy Number Alterations Associated with Japanese or Endometriosis in Ovarian Clear Cell Adenocarcinoma
Aikou Okamoto et al.
PLOS ONE (2015)
The role of DNA repair pathways in cisplatin resistant lung cancer
Shane O'Grady et al.
CANCER TREATMENT REVIEWS (2014)
Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance
Oliver Bruhn et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)
Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers
Shinya Matsuzaki et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer
Leonardo Mirandola et al.
GYNECOLOGIC ONCOLOGY (2014)
mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review
Nader Husseinzadeh et al.
GYNECOLOGIC ONCOLOGY (2014)
Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A
Shinya Matsuzaki et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis
Bin Guan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma
Hsien-Neng Huang et al.
MODERN PATHOLOGY (2014)
Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer
Hao Zhang et al.
PLOS ONE (2014)
The target therapy of ovarian clear cell carcinoma
Ying Jin et al.
ONCOTARGETS AND THERAPY (2014)
Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner
Akiko Morimoto et al.
ONCOTARGET (2014)
Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinoma
Xiang Qi et al.
ONCOTARGET (2014)
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
D. S. P. Tan et al.
BRITISH JOURNAL OF CANCER (2013)
Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer
Pengnan Zhang et al.
CARCINOGENESIS (2013)
Angiogenesis as a target for the treatment of ovarian cancer
Danielle Shaw et al.
CURRENT OPINION IN ONCOLOGY (2013)
A review of iniparib in ovarian cancer
Ivy Wilkinson-Ryan et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer
K. M. Moxley et al.
GYNECOLOGIC ONCOLOGY (2013)
The roles of ARID1A in gynecologic cancer
Tsui-Lien Mao et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2013)
Transformation to high grade neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma
S. Popat et al.
LUNG CANCER (2013)
Annexin A4 Is Involved in Proliferation, Chemo-Resistance and Migration and Invasion in Ovarian Clear Cell Adenocarcinoma Cells
Tae Mogami et al.
PLOS ONE (2013)
Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis
Noor A. Lokman et al.
ONCOTARGET (2013)
Nuclear export of proteins and drug resistance in cancer
Joel G. Turner et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Histotype-specific copy-number alterations in ovarian cancer
Ruby YunJu Huang et al.
BMC MEDICAL GENOMICS (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma
Mohammed Tanjimur Rahman et al.
CANCER (2012)
Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells
Tsuyoshi Ohta et al.
CANCER BIOLOGY & THERAPY (2012)
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
Ting Gui et al.
CANCER EPIDEMIOLOGY (2012)
ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial-Mesenchymal Transition and Invasion
Julie A. Vendrell et al.
CANCER RESEARCH (2012)
Clear cell carcinoma of the ovary: A review of the literature
Marcela G. del Carmen et al.
GYNECOLOGIC ONCOLOGY (2012)
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma
Munmun Rahman et al.
HUMAN PATHOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?
Masashi Takano et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Molecular mechanisms of cisplatin resistance
L. Galluzzi et al.
ONCOGENE (2012)
The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression
Laurie E. Littlepage et al.
CANCER DISCOVERY (2012)
GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response
Baishen Chen et al.
CANCER LETTERS (2011)
Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells
Tsutomu Kobayashi et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
David S. P. Tan et al.
CLINICAL CANCER RESEARCH (2011)
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer
Katherine M. Bell-McGuinn et al.
GYNECOLOGIC ONCOLOGY (2011)
Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010
Michael S. Anglesio et al.
GYNECOLOGIC ONCOLOGY (2011)
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
Sohei Yamamoto et al.
MODERN PATHOLOGY (2011)
Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary
Ayako Kim et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary A JGOG Study
Satoshi Takakura et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Sian Jones et al.
SCIENCE (2010)
Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada
Aziz Aris
JOURNAL OF OVARIAN RESEARCH (2010)
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary
Seiji Mabuchi et al.
CLINICAL CANCER RESEARCH (2009)
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas
David S. P. Tan et al.
CLINICAL CANCER RESEARCH (2009)
Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin
Ayako Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Annexin IV is Differentially Expressed in Clear Cell Carcinoma of the Ovary
Yi Miao et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
The Role of Hepatocyte Nuclear Factor-1β in the Pathogenesis of Clear Cell Carcinoma of the Ovary
Hiroshi Kobayashi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Kim Pedersen et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231
Sei-Ichiro Nakajima et al.
ONCOLOGY REPORTS (2009)
Therapeutic strategy targeting the mTOR-HIF-1 alpha-VEGF pathway in ovarian clear cell adenocarcinoma
Masaki Miyazawa et al.
PATHOLOGY INTERNATIONAL (2009)
Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer
Carol O'Brien et al.
CANCER RESEARCH (2008)
Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology
Sarah C. Shuck et al.
CELL RESEARCH (2008)
Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma
J. A. Rauh-Hain et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells
Niels Eckstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary
T. Oishi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis
Masashi Takano et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
The role of galectin-3 in cancer drug resistance
Tomoharu Fukumori et al.
DRUG RESISTANCE UPDATES (2007)
Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer
T Fukumori et al.
CANCER RESEARCH (2006)
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial
H Utsunomiya et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary
N Kato et al.
MODERN PATHOLOGY (2006)
Identification of target genes of the transcription factor HNF1β and HNF1α in a human embryonic kidney cell line
S Senkel et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2005)
Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma
MM Leitao et al.
GYNECOLOGIC ONCOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: Possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab
M Fujimura et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary
H Itamochi et al.
OBSTETRICS AND GYNECOLOGY (2002)
Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary
H Itamochi et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary
H Itamochi et al.
ONCOLOGY (2002)
分享论文
